MONMOUTH JUNCTION, N.J.,
Oct. 17, 2016 /PRNewswire/ --
CytoSorbents Corporation (NASDAQ: CTSO), a critical care
immunotherapy leader commercializing its flagship CytoSorb®
extracorporeal cytokine adsorber to treat deadly inflammation in
critically-ill and cardiac surgery patients around the world, is
pleased to congratulate Kathleen
Bloch, Chief Financial Officer (CFO) of CytoSorbents, as the
winner of the NJBIZ Public Company CFO of the Year Award, announced
Friday, October 14th at
the annual awards ceremony.
The 2016 NJBIZ CFO of the Year Awards celebrates New Jersey's financial executives at all
levels who contribute to the success of New Jersey's economic growth and
stability.
Dr. Phillip Chan, Chief Executive
Officer of CytoSorbents stated, "We are very proud of Kathy and
this award that reflects her many accomplishments not just at
CytoSorbents, but throughout her long and successful career.
Kathy's contributions to our company run far and wide, and include
for example, helping to establish and execute upon our global
strategy, spearheading the up-listing to NASDAQ and ensuring
ongoing SEC and Sarbanes Oxley compliance, and managing the
financing and financial needs of this rapidly growing, vertically
integrated manufacturer of CytoSorb® that through the effort of
more than 70 employees over 2 continents, is saving lives and
generating strong sales growth across a 40-country network of
distributors, strategic partners, and our own direct sales team.
Congratulations again to Kathy for this well-deserved award."
About NJBIZ
NJBIZ, New Jersey's leading
business journal, produces a weekly print edition with a
circulation of more than 15,000 copies, as well as providing 24/7
business news coverage through its NJBIZ.com website and multiple
daily e-newsletters. The publication, founded in 1987, is
also well-known as the leader of numerous events honoring
New Jersey's top business
professionals.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in critical care
immunotherapy, specializing in blood purification. Its flagship
product, CytoSorb® is approved in the European Union with
distribution in 40 countries around the world, as a safe and
effective extracorporeal cytokine adsorber, designed to reduce the
"cytokine storm" or "cytokine release syndrome" that could
otherwise cause massive inflammation, organ failure and death in
common critical illnesses such as sepsis, burn injury, trauma, lung
injury and pancreatitis, as well as in cancer immunotherapy. These
are conditions where the risk of death is extremely high, yet no
effective treatments exist. CytoSorb® is also being used during and
after cardiac surgery to remove inflammatory mediators, such as
cytokines and free hemoglobin, which can lead to post-operative
complications, including multiple organ failure. CytoSorbents has
completed its REFRESH (REduction in FREe Hemoglobin) 1 trial - a
multi-center, randomized controlled study that has demonstrated the
safety of intra-operative CytoSorb® use in a heart-lung machine
during complex cardiac surgery. In early 2017, the company
plans to initiate a pivotal REFRESH 2 trial intended to support
U.S. FDA approval. CytoSorb® has been used safely in more
than 14,000 human treatments to date.
CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove
toxic substances from blood and other bodily fluids by pore capture
and surface adsorption. Its technologies have received non-dilutive
grant and contract funding in excess of $18
million from DARPA, the U.S. Army, the U.S. Air Force, the
U.S. Department of Health and Human Services, the National
Institutes of Health (NIH), National Heart, Lung, and Blood
Institute (NHLBI), U.S. Special Operations Command (SOCOM) and
others. The Company has numerous products under development based
upon this unique blood purification technology, protected by 32
issued U.S. patents and multiple applications pending, including
CytoSorb-XL, HemoDefend™, ContrastSorb, DrugSorb, and others.
For more information, please visit the Company's websites:
http://www.cytosorbents.com and http://www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking statements intended
to qualify for the safe harbor from liability established by the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements include, but are not limited to,
statements about our plans, objectives, representations and
contentions and are not historical facts and typically are
identified by use of terms such as "may," "should," "could,"
"expect," "plan," "anticipate," "believe," "estimate," "predict,"
"potential," "continue" and similar words, although some
forward-looking statements are expressed differently. You should be
aware that the forward-looking statements in this press release
represent management's current judgment and expectations, but our
actual results, events and performance could differ materially from
those in the forward-looking statements. Factors which could cause
or contribute to such differences include, but are not limited to,
the risks discussed in our Annual Report on Form 10-K, filed with
the SEC on March 9, 2016, as updated by the risks reported in
our Quarterly Reports on Form 10-Q, and in the press releases and
other communications to shareholders issued by us from time to time
which attempt to advise interested parties of the risks and factors
which may affect our business. We caution you not to place undue
reliance upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
Please Click to Follow us on Facebook and Twitter
Cytosorbents
Contact:
Amy Vogel
Investor
Relations
(732) 329-8885 ext.
*825
avogel@cytosorbents.com
|
Public Relations
Contact:
Amy
Phillips
Pascale
Communications
412-327-9499
amy@pascalecommunications.com
|
Logo -
http://photos.prnewswire.com/prnh/20140408/MM00899LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/cytosorbents-congratulates-kathleen-bloch-as-njbiz-public-company-chief-financial-officer-of-the-year-300345629.html
SOURCE CytoSorbents Corporation